Lenvima (lenvatinib) / Eisai, Merck (MSD) 
Welcome,         Profile    Billing    Logout  
 53 Diseases   490 Trials   490 Trials   8927 News 
582 Trials

   

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Lenvima (lenvatinib) / Eisai, Merck (MSD)
ChiCTR2100046490: TACE plus Lenvatinib versus TACE Plus Sorafenib for Unresectable Hepatocellular Carcinoma with Portal Vein Tumor Thrombus

Completed
4
100
 
Lenvatinib ;Sorafenib
West China Hospital, Sichuan University; West China Hospital, Department of Science and Technology of Sichuan Province of China (21YYJC2782) and Health Commission of Sichuan Province (20PJ043)
Liver Cancer
 
 
NCT06195228: A Retrospective and Prospective Real-world Study of Molecular Typing in the Treatment of Advanced Thyroid Cancer

Recruiting
4
200
RoW
dabrafenib plus trametinib with or without PD-1 antibody, entrectinib or larotrectinib with or without anti-PD-1 antibdoy, pralsetinib or selpercatinib with or without anti-PD-1 antibdoy, anlotinib or anlotinib plus anti-PD-1 antibody, lenvatinib plus anti-PD-1 antibody, Other Targets: precise treatment based on the target
Fudan University, Inner Mongolia Cancer Hospital Affiliated To Inner Mongolia Medical University, Shanxi Province Cancer Hospital
Advanced Thyroid Cancer Patients Who Received Target Therapy
04/26
04/27
ChiCTR2000034143: Prospective, single-arm, multicenter clinical study of lenvatinib for adjuvant treatment of HCC patients with high risk of recurrence after hepatectomy.

Recruiting
4
164
 
Lenvatinib
Nangfan Hospital; Nanfang Hospital, Cheng Xiao-ping foundation for the development of science and technology of Hubei province
Hepatocellular Carcinoma
 
 
ChiCTR1900023914: A study of PD-1/PD-L1 inhibitors combined with Lenvatinib for advanced unresectable liver cancer as the neoadjuvant therapy

Recruiting
4
80
 
combination of anti-pd-1 / pd-l1 antibody and Lenvastinib; anti-pd-1 / pd-l1 antibody or Lenvastinib ;neither of anti-pd-1 / pd-l1 antibody or Lenvastinib
Department of Hepatobiliary Surgery Chinese PLA General Hospital & Medical School; Chinese PLA General Hospital & Medical School, Self-fund
Hepatocellular carcinoma
 
 
NCT04127396: Lenvatinib Plus TACE Versus Sorafenib Plus TACE for HCC With PVTT

Enrolling by invitation
4
72
RoW
Lenvatinib Pill, E7080, Transarterial chemoembolization(TACE), Sorafenib
Beijing Ditan Hospital
Carcinoma, Hepatocellular, Portal Vein Tumor Thrombus
08/21
12/21
ChiCTR2100054077: Efficacy and safety of Zimberelimab plus Lenvatinib as first-line treatment in unresectable or metastatic hepatocellular carcinoma patients: a single arm, prospective clinical study

Recruiting
4
32
 
Zimberelimab plus Lenvatinib
Jiansu Cancer Hospital; Jiansu Cancer Hospital, self-funded
Hepatocellular Carcinoma
 
 
ChiCTR2200059078: A prospective, small sample and observational study of TACE combined with portal vein tumor thrombus seed implantation and Lenvatinib in the treatment of HCC with portal vein tumor thrombus

Not yet recruiting
4
30
 
TACE combined with particle implantation combined with Lenvatinib
Henan Cancer Hospital; Henan Cancer Hospital, Self-financing
Hepatocellular Carcinoma with Portal Vein Canc
 
 
ChiCTR1900027953: A multicenter prospective cohort study for relapse prevention in patients with high-risk recurrence after primary hepatocellular carcinoma resection

Recruiting
4
412
 
Lenvatinib ;Blank
Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University; Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangdong Medical Doctor Association
Hepatocellular carcinoma
 
 
ChiCTR2000033343: A prospective randomized controlled clinical study of the efficacy of lenvatinib combined with TACE versus TACE alone in patients with advanced first-line unresectable hepatitis B infection

Not yet recruiting
4
176
 
Lenvatinib combined with TACE ;TACE
The First Affiliated Hospital of Zhejiang University; The First Affiliated Hospital of Zhejiang University, Patients purchase medicines at their own expense, hospital scientific research funding
Hepatocellular carcinoma
 
 
NCT04297254: A Study to Assess the Safety and Efficacy of Lenvatinib as First-line Treatment in Participants With Unresectable HCC

Completed
4
50
RoW
Lenvatinib
Eisai Pharmaceuticals India Pvt. Ltd
Carcinoma, Hepatocellular
07/23
07/23
ChiCTR2200056181: Single-arm and exploratory clinical study of lenvatinib, tirelizumab and radiotherapy combined with HAIC in the treatment of hepatocellular carcinoma with portal vein tumor thrombus

Recruiting
4
38
China
Lenvatinib+Tislelizumab+Radiotherapy + Hepatic Artery Infusion Chemotherapy (HAIC)
Zhongshan Hospital Xiamen University; Zhongshan Hospital Xiamen University, self-funded
Hepatocellular carcinoma
 
 
ChiCTR2100042270: A prospective, randomized controlled, open-label clinical study of lenvatinib + camrelizumab + TACE +versus lenvatinib + camrelizumab in the treatment of advanced liver cancer

Recruiting
4
58
 
lenvatinib + camrelizumab +TACE ;lenvatinib + camrelizumab
Affiliated Tumor Hospital of Guangxi Medical University; Affiliated Tumor Hospital of Guangxi Medical University, self-raised
Primary liver cancer
 
 
NCT06311929: Precision Adjuvant Therapy After Surgery for Hepatocellular Carcinoma

Recruiting
4
300
RoW
PD-1 monoclonal antibody and lenvatinib, Non, PD-1 monoclonal antibody
Chen Xiaoping
HCC
12/27
12/28
NCT06311942: Triple vs. Dual Adjuvant Therapy Following Liver Resection for HCC.

Recruiting
4
300
RoW
HAIC plus PD-1 inhibitors plus lenvatinib, Non, PD-1 inhibitors plus lenvatinib
Chen Xiaoping
HCC
12/27
12/28
NCT03573960: A Study to Evaluate the Safety and Efficacy of Lenvatinib in Participants With Refractory Differentiated Thyroid Cancer

Active, not recruiting
4
50
RoW
Lenvatinib
Eisai Pharmaceuticals India Pvt. Ltd
Thyroid Neoplasms
12/24
12/24
NCT06311916: Efficacy and Safety of Neoadjuvant Therapy in Patients With Resectable HCC Screened by a Multimodal Deep Learning Model.

Not yet recruiting
4
312
NA
HAIC + Tirelizumab +lenvatinib +liver resection, Non, liver resection
Chen Xiaoping
HCC
12/27
12/28
NCT06417606: Lenvatinib and Adebrelimab Combined With GEMOX in the Perioperative Treatment of Potentially Resectable Intrahepatic Cholangiocarcinoma

Not yet recruiting
4
20
RoW
Lenvatinib, Adebrelimab, GEMOX(Gemcitabine and oxaliplatin)
Zhiyong Huang
Intrahepatic Cholangiocarcinoma
04/25
05/25
NCT05673824: Effect of Huaier Granule on Nephrotoxicity Associated With Targeted Therapy for Advanced Hepatobiliary Malignancies.

Recruiting
4
53
RoW
Huaier Granule, VEGFR-TKIs
Fudan University, LinkDoc Technology (Beijing) Co. Ltd.
Nephrotoxicity
02/25
04/25
ChiCTR2100047099: A single center real-world study of Lenvatinib in the treatment of locally advanced differentiated thyroid cancer

Recruiting
4
12
 
Nil
Fujian Cancer Hospital; Fujian Cancer Hospital, self-funded
differentiated thyroid cancer
 
 
NCT06003673: A Clinical Study of Tislelizumab Combined With TACE and Lenvatinib in the Neoadjuvant Treatment of Resectable HCC

Recruiting
4
20
RoW
neoadjuvant therapy
First Affiliated Hospital of Fujian Medical University
Hepatocellular Carcinoma Resectable
07/24
07/25
ChiCTR2200061888: An exploratory study of pembrolizumab combined with lenvatinib mesylate for first-line treatment of advanced hepatocellular carcinoma

Not yet recruiting
4
43
China
Pembrolizumab in combination with lenvatinib
Tangdu Hospital, Air Force Military Medical University ; Tangdu Hospital, Air Force Military Medical University, self-funded
hepatocellular carcinoma
 
 
NCT06499610: Clinical Study of Irinotecan Liposome Combination Therapy for Advanced Gastric Cancer

Not yet recruiting
4
44
RoW
Irinotecan Hydrochloride Liposome Injection, Sintilimab Injection, Lenvatinib Mesilate Capsules
First Affiliated Hospital Xi'an Jiaotong University
Gastric Cancer
10/27
10/27
ChiCTR2000035161: Single arm clinical study of Lenvatinib combined with Camrelizumab as the first-line treatment of advanced hepatocellular carcinoma

Recruiting
4
72
 
Lenvatinib combined with Camrelizumab
Guangdong General Hospital; Guangdong General Hospital, Bethune Charitable Foundation; Heart to Heart Foundation
hepatocellular carcinoma
 
 
ChiCTR2200057630: A randomized, open label, controlled trial for Arsenic trioxide combined with Lenvatinib in the treatment of advanced unresectable hepatocellular carcinoma

Not yet recruiting
4
146
 
Renvatinib ;Renvatinib + Arsenic Trioxide
Shanghai Changhai Hospital; Changhai Hospital, Shanghai Special Project of Integrated Traditional Chinese and Western Medicine
hepatocellular carcinoma
 
 
ChiCTR2100052881: A clinical study of hepatic artery infusion chemotherapy combined with lenvatinib bridging therapy before liver transplantation for primary hepatic carcinoma exceeding milan criteria

Recruiting
4
30
 
HAIC(hepatic artery infusion chemotherapy) combined with Lenvatinib
The Third Affiliated Hospital of Sun Yat-Sen University; The Third Affiliated Hospital of Sun Yat-Sen University, The Bethune Liver Cancer Research Program
Primary hepatic carcinoma
 
 
OPTI-DOSE, NCT05949424: OPTI - DOSE: Optimal Dosing of Oral Anticancer Drugs in Older Adults

Not yet recruiting
4
30
Europe
Olaparib, Lynparza, Lenvatinib, Lenvima, Sunitinib, Sutent, Palbociclib, Ibrance, Pazopanib, Votrient
University Medical Center Groningen
Renal Cell Carcinoma, Ovarian Carcinoma, Thyroid Carcinoma, Breast Carcinoma, Endometrium Carcinoma
03/25
03/25
ChiCTR2300069480: Transformation therapy of locally advanced gallbladder cancer with camrelizumab combined with lenvatinib: a single-center, single-arm, exploratory clinical study

Not yet recruiting
4
25
 
Preoperative: Karelizumab 200 mg q2w, orally administered with rivatinib once daily for 2-8 cycles. Evaluate the efficacy every 2 cycles, and then perform surgery; Postoperative: Original adjuvant therapy, up to one year
Qingdao University Affiliated Hospital; The Affiliated Hospital of Qingdao University, self-funded
Cholangiocarcinoma
 
 
ChiCTR2300073121: Camrelizumab combined with TACE and targeted therapy VS TACE combined with targeted therapy for primary hepatocellular carcinoma with portal vein tumor thrombus: a comparative study

Not yet recruiting
4
78
 
Carrelizumab combined with D-TACE and targeted therapy, this group of patients received D-TACE and intraoperative intraoperative intravenous infusion of carrelizumab 200 mg, and oral lenvatinib 8 mg QD (body weight < 60 kg) or 12 mg QD (body weight >=60 kg) was started on days 3 to 7 after D-TACE according to the patient's recovery. Carrelizumab 200 mg IV is given every three weeks. In the first half of the year, blood and imaging tests are routinely reviewed every 4-8 weeks, and D-TACE treatment is repeated as needed according to the results of the review. If the patient's condition is stable, the interval between re-examination will be extended after six months according to the actual situation. ;The patients in this group were treated with 8 mgQD (body weight < 60kg) or 12 mgQD (body weight >= 60kg) on the 3-7 days after D-TACE.
The First Affiliated Hospital, Zhejiang University School of Medicine; The First Affiliated Hospital, Zhejiang University School of Medicine, BEIJING MEDICAL AWARD FOUNDATION
primary hepatocellular carcinoma with portal vein tumor thrombus
 
 
ChiCTR2300068266: Tirelizumab plus Lunvatinib and capecitabine for first-line treatment of advanced intrahepatic cholangiocarcinoma unsuitable for GP chemotherapy

Not yet recruiting
4
36
China
1. Tirelizumab: 200mg, q3w, intravenous drip, lasting for 1 year, or until the disease progresses or intolerable adverse reactions occur; 2. Remvastinib: 8mg, qd, oral, until the disease progresses or intolerable adverse reactions occur; 3. Capecitabine: 1000mg/m2, bid, oral, take it for 2 weeks, stop for 1 week
The Third Affiliated Hospital of Naval Medical University (Eastern Hepatobiliary Surgery Hospital) ; The Third Affiliated Hospital of Naval Medical University (Eastern Hepatobiliary Surgery Hospital), BeiGene (Beijing), Ltd.
advanced intrahepatic cholangiocarcinoma
 
 
ChiCTR2300071610: A prospective study of the effect of preoperative neoadjuvant therapy of Lenvatinib combined with Camrelizumab on prognosis of patients with high risk of recurrence of hepatocellular carcinoma

Not yet recruiting
4
60
 
Preoperative adjuvant medication
Mengchao Hepatobiliary Hospital of Fujian Medical University; Mengchao Hepatobiliary Hospital of Fujian Medical University, self-funded
Hepatocellular carcinoma
 
 

Recruiting
4
56
 
High-dose irradiation plus low-dose radiatlion combined with tislelizumab and lenvatinib
Pingxiang People's Hospital; Pingxiang People's Hospital, Pingxiang People's Hospital
hepatocellular carcinoma
 
 
ChiCTR2300076540: A multicenter, prospective, exploratory research study of modified DEB-TACE in the treatment of unresectable large liver cancer in Shandong

Not yet recruiting
4
78
 
Modified DEB-TACE+Lenvatinib+Camrelizumab
Linyi Cancer Hospital; Linyi Cancer Hospital, raised independently
Hepatocellular carcinoma
 
 
2020-004437-20: A clinical study to compare Toripalimab (JS001) combined with Lenvatinib versus placebo combined with Lenvatinib as the 1st-line therapy for advanced hepatocellular carcinoma (HCC)

Ongoing
3
519
Europe
Toripalimab, LENVIMA, TAB001 and JS001, Solution for infusion, Capsule, hard, LENVIMA
Shanghai Junshi Biosciences Co., Ltd, Shanghai Junshi Biosciences Co., Ltd., Shanghai Junshi Biosciences Co., Ltd
advanced hepatocellular carcinoma (HCC), liver cancer, Diseases [C] - Cancer [C04]
 
 
2018-002520-16: Pembrolizumab plus Lenvatinib as First-line Intervention for Advanced Melanoma

Not yet recruiting
3
790
Europe, RoW
PEMBROLIZUMAB, KEYTRUDA (pembrolizumab, MK-3475), Lenvatinib, MK-3475, E7080, Solution for infusion, Capsule, hard, KEYTRUDA (pembrolizumab, MK-3475)
Merck Sharp & Dohme LLC, Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., MERCK SHARP & DOHME CORP. UNA SUSSIDIARIA DI MERCK & CO. INC., Merck Sharp & Dohme LLC, Eisai Ltd, Merck Sharp & Dohme Corp.LLC, a subsidiary of Merck & Co., Inc., Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Merck Sharp & Dohme LLC., Eisai Ltd.
Unresectable Stage III and Stage IV melanoma, Advanced melanoma, Diseases [C] - Cancer [C04]
 
 
2018-002983-26: Phase 3 Study of Lenvatinib (E7080/MK-7902) plus Pembrolizumab (MK- 3475) for First-line Therapy of Advanced Hepatocellular Carcinoma

Not yet recruiting
3
750
Europe
PEMBROLIZUMAB, KEYTRUDA (pembrolizumab, MK-3475), Lenvatinib, MK-3475, E7080, Solution for infusion, Capsule, hard, KEYTRUDA (pembrolizumab, MK-3475)
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Merck Sharp & Dohme LLC, MERCK SHARP & DOHME CORP. UNA SUSSIDIARIA DI MERCK & CO. INC., Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Eisai Limited., Merck Sharp & Dohme LLC, Eisai Limited, Eisai Ltd., Eisai Ltd
Advanced hepatocellular carcinoma, Advanced hepatocellular carcinoma without any prior systemic treatment, Diseases [C] - Cancer [C04]
 
 
2018-003009-24: Pembrolizumab and lenvatinib versus chemotherapy for advanced, recurrent, or metastatic endometrial cancer

Not yet recruiting
3
875
Europe, RoW
KEYTRUDA® (pembrolizumab, MK-3475), PEMBROLIZUMAB, Lenvatinib, Paclitaxel Amneal, Paclitaxel, Carboplatin, Paclitaxel Ever Pharma, MK-3475, E7080; MK-7902, Solution for infusion, Capsule, hard, Concentrate for solution for infusion, Concentrate for solution for injection/infusion, KEYTRUDA® (pembrolizumab, MK-3475), Paclitaxel Amneal, Paclitaxel Ever Pharma
Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Merck Sharp & Dohme LLC, Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., MERCK SHARP & DOHME CORP. UNA SUSSIDIARIA DI MERCK & CO. INC., Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Eisai Limited, Merck Sharp & Dohme LLC, Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
Advanced Endometrial Cancer, Advanced Endometrial Cancer is the cancer of the lining of the uterus (or womb)., Diseases [C] - Cancer [C04]
 
 
CLEAR trial, NCT02811861 / 2016-000916-14: Lenvatinib/Everolimus or Lenvatinib/Pembrolizumab Versus Sunitinib Alone as Treatment of Advanced Renal Cell Carcinoma

Checkmark Presentation of data from CLEAR trial in advanced RCC at IKCS 2022
Nov 2022 - Nov 2022: Presentation of data from CLEAR trial in advanced RCC at IKCS 2022
Checkmark Data from CLEAR trial in combination with Lenvima for RCC at ESMO 2022
Sep 2022 - Sep 2022: Data from CLEAR trial in combination with Lenvima for RCC at ESMO 2022
Checkmark Data from CLEAR trial in combination with Lenvima for RCC at ASCO 2022
More
Active, not recruiting
3
1069
Europe, Canada, Japan, US, RoW
Lenvatinib, Everolimus, Pembrolizumab, Sunitinib
Eisai Inc., Merck Sharp & Dohme LLC
Renal Cell Carcinoma
08/20
03/26
KEYNOTE-775, NCT03517449 / 2017-004387-35: Lenvatinib in Combination With Pembrolizumab Versus Treatment of Physician's Choice in Participants With Advanced Endometrial Cancer (MK-3475-775/E7080-G000-309 Per Merck Standard Convention [])

Checkmark Presentation of data from KEYNOTE-775 trial for solid tumors at ESMO 2022
Sep 2022 - Sep 2022: Presentation of data from KEYNOTE-775 trial for solid tumors at ESMO 2022
Checkmark Approved in Korea in combination with Lenvima for 1L endometrial cancer
Jan 2022 - Jan 2022: Approved in Korea in combination with Lenvima for 1L endometrial cancer
Checkmark Approved in combination with Keytruda for patients with unresectable, advanced or recurrent endometrial carcinoma
More
Active, not recruiting
3
827
Europe, Canada, Japan, US, RoW
Pembrolizumab, KEYTRUDA®, MK-3475, Lenvatinib, LENVIMA®, Paclitaxel, TAXOL®, Doxorubicin, ADRIAMYCIN®
Eisai Inc., Merck Sharp & Dohme LLC
Endometrial Neoplasms
10/20
02/25
2020-004289-20: A Phase 3 Study of Lenvatinib Plus Pembrolizumab in Previously Treated Participants with Metastatic Colorectal Cancer

Not yet recruiting
3
434
Europe
Lenvatinib, E7080, Concentrate for solution for infusion, Capsule, hard, Film-coated tablet, KEYTRUDA (pembrolizumab, MK-3475), STIVARGA, LONSURF
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Merck Sharp & Dohme Corp., a subsidiary of Merck & Co.,Inc
Colorectal Carcinoma, Colorectal cancer, Diseases [C] - Cancer [C04]
 
 
LEAP-007, NCT03829332 / 2018-003794-98: Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (MK-7902/E7080) in Adults With Programmed Cell Death-Ligand 1 (PD-L1)-Positive Treatment-naïve Nonsmall Cell Lung Cancer (NSCLC) (MK-7902-007/E7080-G000-314/)

Completed
3
623
Europe, Canada, Japan, US, RoW
Pembrolizumab, MK-3475, KEYTRUDA®, Lenvatinib, MK-7902, E7080, LENVIMA®, Placebo for lenvatinib
Merck Sharp & Dohme LLC, Eisai Inc.
Non-small Cell Lung Cancer
05/21
04/24
LEAP-007 China Extension, NCT04676412: Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (MK-7902/E7080) in Adults With Programmed Cell Death-Ligand 1 (PD-L1)-Positive Treatment-naïve Nonsmall Cell Lung Cancer (NSCLC) [MK-7902-007/E7080-G000-314/LEAP-007] - China Extension Study

Completed
3
27
RoW
Pembrolizumab, MK-3475, KEYTRUDA®, Lenvatinib, MK-7902, E7080, LENVIMA®, Placebo for lenvatinib
Merck Sharp & Dohme LLC, Eisai Inc.
Non-small Cell Lung Cancer
05/21
03/24
LEAP-011, NCT03898180 / 2018-003752-21: Study of First-line Pembrolizumab (MK-3475) With Lenvatinib (MK-7902/E7080) in Urothelial Carcinoma Cisplatin-ineligible Participants Whose Tumors Express Programmed Cell Death-Ligand 1 and in Participants Ineligible for Platinum-containing Chemotherapy (MK-7902-011/E7080-G000-317/ )

Checkmark From LEAP-011 trial in combination with Lenvima for urothelial carcinoma at ESMO 2019
Sep 2019 - Sep 2019: From LEAP-011 trial in combination with Lenvima for urothelial carcinoma at ESMO 2019
Completed
3
505
Europe, Canada, Japan, US, RoW
Pembrolizumab, MK-3475, KEYTRUDA®, Lenvatinib, MK-7902, E7080, LENVIMA®, Placebo for lenvatinib
Merck Sharp & Dohme LLC, Eisai Inc.
Urothelial Carcinoma
07/21
05/24
RRHCCLT, NCT04237740: Relenvatinib in the Tatment of Recurrence of Hepatocellular Carcinoma After Liver Transplantation

Not yet recruiting
3
40
NA
relenvatinib, relenvatinib treatment
RenJi Hospital
Hepatocellular Carcinoma, Liver Transplantation
01/22
11/22
LEAP-002, NCT03713593: Safety and Efficacy of Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) Versus Lenvatinib as First-line Therapy in Participants With Advanced Hepatocellular Carcinoma (MK-7902-002/E7080-G000-311/)

Hourglass Aug 2024 - Aug 2024 : Trial completion date for LEAP-002 trial for advanced 1L HCC
Checkmark Data from LEAP-002 trial in combination with Keytruda for 1L advanced HCC at ASCO-GI 2023
Jan 2023 - Jan 2023: Data from LEAP-002 trial in combination with Keytruda for 1L advanced HCC at ASCO-GI 2023
Checkmark Data from LEAP-002 trial in combination with Keytruda for 1L advanced HCC at ESMO 2022
Sep 2022 - Sep 2022: Data from LEAP-002 trial in combination with Keytruda for 1L advanced HCC at ESMO 2022
Completed
3
794
Europe, Canada, Japan, US, RoW
lenvatinib, MK-7902, E7080, LENVIMA®, pembrolizumab, MK-3475, KEYTRUDA®, saline placebo
Merck Sharp & Dohme LLC, Eisai Inc.
Carcinoma, Hepatocellular
06/22
09/24
NCT04687163: Sorafenib or Lenvatinib Plus HAIC of 130 mg/m² Oxaliplatin, and 5-fu vs Sorafenib or Lenvatinib Plus HAIC of 85mg/m² Oxaliplatin, and 5-fu for Unresectable Advanced HCC: a Randomised Phase 3 Trial

Recruiting
3
400
RoW
HAIC of 130 mg/m² Oxaliplatin, and 5-fu, HAIC of 85 mg/m² Oxaliplatin, and 5-fu, TKI
Sun Yat-sen University, Kaiping Central Hospital, Guangzhou No.12 People's Hospital
Hepatocellular Carcinoma
12/22
12/22
NCT04229355: DEB-TACE Plus Lenvatinib or Sorafenib or PD-1 Inhibitor for Unresectable Hepatocellular Carcinoma

Recruiting
3
90
RoW
DEB-TACE plus Sorafenib, DEB-TACE plus Lenvatinib, DEB-TACE plus PD-1 inhibitor
Guangxi Medical University
Hepatocellular Carcinoma
12/22
12/22
NCT04053985: The Efficacy of Transarterial Chemoinfusion (TAI) Combine Lenvatinib in Advanced Hepatocellular Carcinoma (HCC)

Recruiting
3
206
RoW
TAI combine lenvatinib, Lenvatinib
Sun Yat-sen University
Hepatocellular Carcinoma
12/22
12/22
NCT04053972: The Impact on Recurrence Risk of Adjuvant Lenvatinib for Patients With Hepatocellular Carcinoma And Microvascular Invasion (MVI) After Hepatectomy : A Random, Controlled, Stage III Clinical Trial.

Recruiting
3
377
RoW
Lenvatinib
Sun Yat-sen University
Hepatocellular Carcinoma
12/22
12/22
LEAP-003, NCT03820986: Safety and Efficacy Study of Pembrolizumab (MK-3475) Combined With Lenvatinib (MK-7902/E7080) as First-line Intervention in Adults With Advance Melanoma (MK-7902-003/E7080-G000-312/)

Completed
3
674
Europe, Canada, US, RoW
Pembrolizumab, MK-3475, KEYTRUDA®, Lenvatinib, MK-7902, E7080, LENVIMA®, Placebo for lenvatinib
Merck Sharp & Dohme LLC, Eisai Inc.
Malignant Melanoma
01/23
11/24
LEAP-003 China Extension, NCT04889118: Safety and Efficacy Study of Pembrolizumab (MK-3475) Combined With Lenvatinib (MK-7902/E7080) as First-line Intervention in Adults With Advanced Melanoma (MK-7902-003/E7080-G000-312/LEAP-003)-China Extension Study

Completed
3
131
RoW
Pembrolizumab, MK-3475, KEYTRUDA®, Lenvatinib, MK-7902, E7080, LENVIMA®, Placebo for lenvatinib
Merck Sharp & Dohme LLC, Eisai Inc.
Malignant Melanoma
01/23
11/24
LEAP-017, NCT04776148 / 2020-004289-20: Study of Lenvatinib (MK-7902/E7080) in Combination With Pembrolizumab (MK-3475) Versus Standard of Care in Participants With Metastatic Colorectal Cancer (MK-7902-017/E7080-G000-325/)

Completed
3
480
Europe, Canada, Japan, US, RoW
pembrolizumab, KEYTRUDA®, MK-3475, lenvatinib, MK-7902, E7080, regorafenib, STIVARGA®, REGONIX®, TAS-102 (trifluridine and tipiracil), LONSURF®
Merck Sharp & Dohme LLC, Eisai Inc.
Colorectal Neoplasms
02/23
09/24
TACE, NCT03905967: With Lenvatinib Versus Lenvatinib Alone in in First-line Treatment of Advanced HCC

Recruiting
3
336
RoW
TACE, Lenvatinib
Sun Yat-sen University
Advanced Hepatocellular Carcinoma
04/23
06/23
LEAP-010, NCT04199104 / 2019-003717-34: A Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (E7080/MK-7902) as First Line (1L) Intervention in a Programmed Cell Death-ligand 1 (PD-L1) Selected Population With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) (MK-7902-010) (KEYNOTE-010)

Active, not recruiting
3
511
Europe, Canada, Japan, US, RoW
Lenvatinib, E7080, MK-7902, LENVIMA®, Pembrolizumab, MK-3475, Keytruda®, Placebo
Merck Sharp & Dohme LLC, Eisai Inc.
Head and Neck Squamous Cell Carcinoma
05/23
03/25
LEAP-006, NCT03829319 / 2018-003824-35: Safety and Efficacy Study of Pemetrexed + Platinum Chemotherapy + Pembrolizumab (MK-3475) With or Without Lenvatinib (MK-7902/E7080) as First-line Intervention in Adults With Metastatic Nonsquamous Non-small Cell Lung Cancer (MK-7902-006/E7080-G000-315/)

Checkmark Data from LEAP-006 trial in combination with pembrolizumab for NSCLC
Sep 2020 - Sep 2020: Data from LEAP-006 trial in combination with pembrolizumab for NSCLC
Checkmark Data from LEAP-006 trial in combination with pembrolizumab & platinum doublet chemo in mNSCLC at ESMO 2020
Jul 2020 - Jul 2020: Data from LEAP-006 trial in combination with pembrolizumab & platinum doublet chemo in mNSCLC at ESMO 2020
Checkmark Data from LEAP-006 trial in combination with lenvatinib & platinum doublet chemo in mNSCLC at ESMO 2020
More
Completed
3
761
Europe, Canada, Japan, US, RoW
Pembrolizumab, MK-3475, Carboplatin, Cisplatin, Pemetrexed, Lenvatinib, MK-7902, E7080, Placebo matching lenvatinib
Merck Sharp & Dohme LLC, Eisai Inc.
Nonsquamous Non-small Cell Lung Cancer
08/23
08/24
LEAP-008, NCT03976375 / 2018-003791-12: Efficacy and Safety of Pembrolizumab (MK-3475) With Lenvatinib (E7080/MK-7902) vs. Docetaxel in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) and Progressive Disease (PD) After Platinum Doublet Chemotherapy and Immunotherapy (MK-7902-008/E7080-G000-316/)

Completed
3
422
Europe, Canada, Japan, US, RoW
Pembrolizumab, MK-3475, KEYTRUDA®, Lenvatinib, MK-7902, E7080, LENVIMA®, Docetaxel, TAXOTERE®
Merck Sharp & Dohme LLC, Eisai Inc.
Metastatic Non-Small Cell Lung Cancer
08/23
08/24
LEAP-006 China Extension, NCT04716933: Safety and Efficacy Study of Pemetrexed + Platinum Chemotherapy + Pembrolizumab (MK-3475) With or Without Lenvatinib (MK-7902/E7080) as First-line Intervention in Adults With Metastatic Nonsquamous Non-small Cell Lung Cancer (MK-7902-006/E7080-G000-315/LEAP-006)-China Extension Study

Completed
3
201
RoW
Pembrolizumab, MK-3475, Carboplatin, Cisplatin, Pemetrexed, Lenvatinib, MK-7902, E7080, Placebo matching lenvatinib
Merck Sharp & Dohme LLC, Eisai Inc.
Nonsquamous Non-small Cell Lung Cancer
08/23
08/24
LEAP-001, NCT03884101 / 2018-003009-24: Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Versus Chemotherapy for Endometrial Carcinoma (ENGOT-en9 / MK-7902-001)

Checkmark From ENGOT-en9 trial in combination with Lenvima for endometrial cancer at ESMO 2019
Sep 2019 - Sep 2019: From ENGOT-en9 trial in combination with Lenvima for endometrial cancer at ESMO 2019
Completed
3
842
Europe, Canada, Japan, US, RoW
Lenvatinib, E7080, MK-7902, LENVIMA®, Pembrolizumab, MK-3475, KEYTRUDA®, Paclitaxel, TAXOL®, ONXAL®, Carboplatin, PARAPLATIN®
Merck Sharp & Dohme LLC, Eisai Inc.
Endometrial Neoplasms
10/23
02/25
NCT05056337: Toripalimab in Combination With Lenvatinib and TACE for Conversion Therapy in Patients With Potentially Resectable HCC

Enrolling by invitation
3
220
RoW
Lenvatinib 4 MG Oral Capsule [Lenvima], Toripalimab, TACE
Shanghai Zhongshan Hospital
Hepatocellular Carcinoma
11/23
12/23
ChiCTR2100052460: Camrelizumab plus Lenvatinib versus Lenvatinib as first-line therapy for advanced primary liver cancer: a phase III, multicenter, randomized controlled clinical trial

Not yet recruiting
3
306
 
Camrelizumab plus Lenvatinib ;Lenvatinib
the First Affiliated Hospital, Sun Yat-Sen University; the First Affiliated Hospital, Sun Yat-Sen University, Clinical research funds of the First Affiliated Hospital, Sun Yat-Sen University
Hepatocellular carcinoma
 
 
NCT06201065: FOLFOX-HAIC Plus Lenvatinib and Toripalimab vs. FOLFOX-HAIC Plus Lenvatinib for Advanced Hepatocellular Carcinoma: a Randomized Controlled and Double-blind Trial

Recruiting
3
200
RoW
Hepatic arterial infusion chemotherapy, Lenvatinib, Toripalimab, oxaliplatin , fluorouracil, and leucovorin
Sun Yat-sen University
Hepatocellular Carcinoma
07/25
12/26
NCT05220020: TACE Combined With Lenvatinib Versus TACE Sequential Lenvatinib in the Treatment of Intermediate/Advanced Liver Cancer

Recruiting
3
299
RoW
TACE(Transcatheter arterial chemoembolization), Lenvatinib, Lenvatinib oral
Sun Yat-sen University
Hepatocellular Carcinoma
02/24
02/25
CARE1, NCT06364631: Pragmatic Clinical Trial

Recruiting
3
1250
Europe, RoW
Nivolumab, OPDIVO, Ipilimumab, YERVOY, Pembrolizumab, KEYTRUDA, Cabozantinib, CABOMETYX, Axitinib, INLYTA, Lenvatinib, LENVIMA
Gustave Roussy, Cancer Campus, Grand Paris, European Commission, CRIS Cancer Foundation, National Cancer Institute, France, Rennes University Hospital, University Hospital, Essen, Fundació Privada Institut d'Investigació Oncològica de Vall d'Hebron, The Netherlands Cancer Institute, Servicio Madrileño de Salud, Madrid, Spain, Hospital Universitario 12 de Octubre, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Medical University of Vienna, FAKULTNI NEMOCNICE OLOMOUC, International Kidney Cancer Coalition, Association pour la Recherche sur les Tumeurs du Rein, Resilience, PRIMAA, Queen Mary University of London
Metastatic Kidney Cancer, Metastatic Kidney Carcinoma
05/32
05/32
LEAP-001 China Extension, NCT04865289: Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Versus Chemotherapy for Endometrial Carcinoma (ENGOT-en9 / MK-7902-001) - China Extension Study

Completed
3
130
RoW
Lenvatinib, E7080, MK-7902, LENVIMA®, Pembrolizumab, MK-3475, KEYTRUDA®, Paclitaxel, TAXOL®, ONXAL®, Carboplatin, PARAPLATIN®
Merck Sharp & Dohme LLC, Eisai Inc.
Endometrial Neoplasms
10/23
01/25
JS001-027-III-HCC, NCT04523493 / 2020-004437-20: Phase III Study of Toripalimab(JS001) Combined With Lenvatinib for Advanced HCC

Active, not recruiting
3
530
Europe, RoW
Toripalimab combined with Lenvatinib, Placebo combined with Lenvatinib
Shanghai Junshi Bioscience Co., Ltd., Shanghai Junshi Biosciences Co., Ltd
Advanced Hepatocellular Carcinoma (HCC)
05/25
09/26
BGB-A317-290-LTE1, NCT04164199 / 2019-002554-23: Study of Tislelizumab, Pamiparib, and Other Investigational Agents in Participants With Advanced Malignancies

Enrolling by invitation
3
300
Europe, Japan, US, RoW
Tislelizumab, BGB-A317, Pamiparib, BGB-290, Temozolomide, Sitravatinib, Ociperlimab, BGB-A1217, BAT1706, Fruquintinib, BGB-15025, Zanidatamab, ZW25, BGB-A445, Surzebiclimab, Lenvatinib, LBL-007
BeiGene
Advanced Malignancies
12/26
12/26
NCT06492395: Lenvatinib Plus DEB-TACE and HAIC Vs. Lenvatinib Plus DEB-TACE for Large HCC with PVTT

Recruiting
3
178
RoW
Len+DEB-TACE+HAIC, Len+DEB-TACE
Second Affiliated Hospital of Guangzhou Medical University
Hepatocellular Carcinoma Non-resectable
07/26
07/27
AK104-308, NCT06371157: A Study of AK104+Lenvatinib in Combination With Transarterial Chemoembolization (TACE) Versus TACE in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma

Recruiting
3
469
RoW
AK104, Lenvatinib, TACE, Placebo for AK104, Placebo for Lenvatinib
Akeso
Hepatocellular Carcinoma
10/25
05/26
STROKER, NCT06726421: Systemic Therapy Alone or with Stereotactic Body Radiotherapy for Oligometastatic Kidney Cancer ( Study)

Recruiting
3
252
RoW
Stereotactic body radiotherapy (SBRT), Stereotactic ablative radiotherapy, axitinib ± immune checkpoint inhibitors (ICIs), lenvatinib ± ICIs, cabozantinib ± ICIs, sunitinib and pazopanib, Standard systemic therapy
Sun Yat-sen University
Renal Cell Carcinoma (Kidney Cancer), Kidney Cancer Metastatic, Renal Cell Carcinoma Metastatic
09/30
09/33
IMbrave251, NCT04770896 / 2020-005231-78: A Study of Atezolizumab With Lenvatinib or Sorafenib Versus Lenvatinib or Sorafenib Alone in Hepatocellular Carcinoma Previously Treated With Atezolizumab and Bevacizumab

Active, not recruiting
3
554
Europe, Canada, Japan, RoW
Atezolizumab, Tecentriq, Lenvatinib, Sorafenib
Hoffmann-La Roche
Unresectable Hepatocellular Carcinoma
07/25
10/25
Adjuvant-02, NCT06089382: A Study to Evaluate Sintilimab Plus Lenvatinib as Adjuvant Therapy in Hepatocellular Carcinoma With Portal Vein Tumor Thrombosis (PVTT) After Surgical Resection

Not yet recruiting
3
104
RoW
Sintilimab, IBI 308, Lenvatinib, LENVIMA, Transarterial Chemoembolization (TACE)
Tongji Hospital
Hepatocellular Carcinoma
11/24
11/26
LEN-TAC, NCT05738616: Lenvatinib Combined With TACE and Camrelizumab in Conversion Resection for Advanced Hepatocellular Carcinoma ( Study)

Recruiting
3
196
RoW
Lenvatinib combined with TACE and Camrelizumab
Wen Tianfu
Advanced Hepatocellular Carcinoma
05/27
12/27
ChiCTR2200064384: Efficacy and Safety of Hepatic Arterial Infusion Chemotherapy (HAIC) combined with Lenvatinib and Tislelizumab for Unresectable Hepatocellular Carcinoma

Recruiting
3
50
 
1
The Second Affiliated Hospital of Nanchang University; The Second Affiliated Hospital of Nanchang University, The Second Affiliated Hospital of Nanchang University
hepatocellular carcinoma
 
 
PREVENT-2, NCT05910970: Adjuvant Tislelizumab Plus Lenvatinib for Patients at High-risk of HCC Recurrence After Curative Resection or Ablation

Not yet recruiting
3
200
RoW
Adjuvant tislelizumab plus lenvatinib, Adjuvant tislelizumab
Guangxi Medical University
Hepatocellular Carcinoma, Recurrence, Immune Checkpoint Inhibitor
12/25
12/25
CS1003-305, NCT04194775 / 2019-003337-41: A Study of Nofazinlimab (CS1003) in Subjects With Advanced Hepatocellular Carcinoma

Active, not recruiting
3
534
Europe, US, RoW
Nofazinlimab (CS1003)+Lenvatinib, Nofazinlimab (CS1003) Placebo+Lenvatinib
CStone Pharmaceuticals
Hepatocellular Carcinoma
06/25
06/25
ChiCTR2300072771: Clinical study of lenvatinib in the treatment of intermediate stage liver cancer after failure of transcatheter arterial chemoembolization

Not yet recruiting
3
66
 
lenvatinib ;Sorafenib
Beijing Ditan Hospital, Capital Medical University; Beijing Ditan Hospital, Capital Medical University, Beijing Municipal Hospital Scientific Research Cultivation Program
hepatocellular carcinoma
 
 
NCT05077215: Efficacy and Safety of a Repurposed Drug Added to the Combination of Len Plus Pem in Advanced Endometrial Cancer

Not yet recruiting
3
450
NA
EG-007, Pembrolizumab 100 mg/ 4 ml (25 mg/ml) Injection, Lenvatinib Capsules
Evergreen Therapeutics, Inc.
Advanced Endometrial Cancer
12/26
12/26
LEAP-014, NCT04949256 / 2020-001911-26: Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Plus Chemotherapy in Participants With Metastatic Esophageal Carcinoma (MK-7902-014/E7080-G000-320/)

Hourglass Jan 2022 - Jan 2022 : Data from LEAP trial in combination with Keytruda for esophageal squamous cell carcinoma at ASCO-GI 2022
Active, not recruiting
3
862
Europe, Canada, Japan, US, RoW
Pembrolizumab, MK-3475, KEYTRUDA®, Lenvatinib, MK-7902, E7080, LENVIMA®, Cisplatin, PLATINOL®, 5-FU, ADRUCIL®, Oxaliplatin, ELOXATIN®, Leucovorin, calcium folinate, folinic acid, WELLCOVORIN®, Levoleucovorin, calcium levofolinate, levofolinic acid, FUSILEV®, Paclitaxel, TAXOL®, ONXAL®
Merck Sharp & Dohme LLC, Eisai Inc.
Metastatic Esophageal Squamous Cell Carcinoma
01/27
01/27
EMERALD-3, NCT05301842 / 2021-003822-54: Evaluate Durvalumab and Tremelimumab +/- Lenvatinib in Combination With TACE in Patients With Locoregional HCC

Jan 2024 - Dec 2024: Data from EMERALD-3 trial in combination with tremelimumab for HCC
Jan 2024 - Dec 2024: Acceptance of regulatory submission in combination with Imfinzi for HCC (based on EMERALD-3 trial)
Jan 2024 - Dec 2024: Acceptance of regulatory submission in combination with tremelimumab for HCC (based on EMERALD-3 trial)
Active, not recruiting
3
760
Europe, Canada, Japan, US, RoW
Tremelimumab, MEDI1123, Durvalumab, MEDI4736, Transarterial Chemoembolization (TACE), DEB-TACE and cTACE, Lenvatinib, Lenvima
AstraZeneca
Hepatocellular Carcinoma
12/25
02/27
ChiCTR2200066830: Clinical study of TACE combined with lenvatinib plus sintilimab in the treatment of hepatocellular carcinoma with portal vein tumor thrombus

Not yet recruiting
3
218
 
TACE combined with lenvatinib plus sintilimab ;TACE combined with lenvatinib
Beijing Ditan Hospital, Capital Medical University; Beijing Ditan Hospital, Capital Medical University, Capital Health Development Scientific Research Project
Hepatocellular carcinoma
 
 
ChiCTR2300076242: Canceled by the investigator. Clinical study on the first-line treatment of advanced hepatocellular carcinoma with B-grade liver function using lenvatinib combined with sintilimab and compared to donafenib combined with sintilimab

Not yet recruiting
3
148
 
lenvatinib combined with sintilimab; Donafenib combined with sintilimab
Beijing Ditan Hospital, Capital Medical University; Beijing Ditan Hospital, Capital Medical University, investigator initiated trial (IIT)
hepatocellular carcinoma
 
 
LEAP-015, NCT04662710 / 2020-001990-53: Efficacy and Safety of Lenvatinib (E7080/MK-7902) Plus Pembrolizumab (MK-3475) Plus Chemotherapy in Participants With Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-7902-015/E7080-G000-321/)

Active, not recruiting
3
895
Europe, Canada, Japan, US, RoW
Pembrolizumab, MK-3475, Keytruda®, Lenvatinib, MK-7902, E7080, Oxaliplatin, Capecitabine, Leucovorin (or Levoleucovorin), 5-FU
Merck Sharp & Dohme LLC, Eisai Inc.
Advanced/Metastatic Gastroesophageal Adenocarcinoma
10/24
03/26
LITESPARK-011, NCT04586231 / 2020-002075-35: A Study of Belzutifan (MK-6482) in Combination With Lenvatinib Versus Cabozantinib for Treatment of Renal Cell Carcinoma (MK-6482-011)

Active, not recruiting
3
708
Europe, Canada, Japan, US, RoW
Belzutifan, PT2977, MK-6482, WELIREG™, Lenvatinib, Lenvima, E7080, MK-7902, Cabozantinib, Cabometyx, Cometriq, XL184, BMS-907351
Merck Sharp & Dohme LLC, Eisai Inc.
Carcinoma, Renal Cell
02/26
02/26
ChiCTR2400087138: A Phase III, Randomized, Double-blinded, Multicenter Study of Cadonilimab (AK104) + Lenvatinib in Combination With Transarterial Chemoembolization (TACE) Versus TACE in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma

Recruiting
3
469
 
Cadonilimab(AK104) + Lenvatinib+ Transarterial Chemoembolization (TACE); Placebo for AK104+ Placebo for Lenvatinib+ Transarterial Chemoembolization (TACE); Cadonilimab(AK104) + Placebo for Lenvatinib+ Transarterial Chemoembolization (TACE)
Zhongda Hospital Southeast University; Zhongda Hospital Southeast University, Akeso Pharma Co., Ltd.
Hepatocellular carcinoma
 
 
MK-7902-010 China Extension, NCT05523323: A Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (E7080/MK-7902) as First Line (1L) Intervention in a Programmed Cell Death-ligand 1 (PD-L1) Selected Population With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) (MK-7902-010/LEAP-010)-China Extension

Active, not recruiting
3
112
RoW
Lenvatinib, E7080, MK-7902, LENVIMA®, Pembrolizumab, MK-3475, Keytruda®, Placebo
Merck Sharp & Dohme LLC, Eisai Inc.
Head and Neck Squamous Cell Carcinoma
08/23
03/25
CheckMate 9DW, NCT04039607 / 2019-000252-34: A Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Hepatocellular Carcinoma

Calendar Jan 2025 - Dec 2025: Data readout from CheckMate 9DW trial for 1L HCC
Hourglass Jan 2020 - Jun 2020 : Submission in Japan for 2L ovarian cancer
Hourglass Jan 2017 - Dec 2018 : Completion of recruitment (advanced solid malignancies)
Active, not recruiting
3
732
Europe, Canada, Japan, US, RoW
Nivolumab, Ipilimumab, Sorafenib, lenvatinib
Bristol-Myers Squibb, Bristol-Myers Squibb International Corporation
Hepatocellular Carcinoma
09/26
09/26
MK-6482-012, NCT04736706 / 2020-002216-52: A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, Versus Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma

Active, not recruiting
3
1653
Europe, Canada, Japan, US, RoW
Pembrolizumab, MK-3475, KEYTRUDA®, Belzutifan, MK-6482, PT2977, WELIREG™, Pembrolizumab/Quavonlimab, MK-1308A, Lenvatinib, MK-7902, E7080, LENVIMA®
Merck Sharp & Dohme LLC, Eisai Inc.
Carcinoma, Renal Cell
10/26
10/26
NCT05608213: Lenvatinib Plus I-125 Seed Brachytherapy vs. Lenvatinib for TACE-refractory HCC

Recruiting
3
187
RoW
Lenvatinib Plus I-125 Seed Brachytherapy, Lenvatinib
Second Affiliated Hospital of Guangzhou Medical University
Hepatocellular Carcinoma Non-resectable
10/26
12/26
NCT05608200: Lenvatinib+Sintilimab+TACE vs. Lenvatinib+TACE for Advanced HCC

Recruiting
3
427
RoW
Lenvatinib, sintilimab plus TACE, Lenvatinib plus TACE
Second Affiliated Hospital of Guangzhou Medical University
Hepatocellular Carcinoma Non-resectable
10/26
10/26
NCT05823311: Lenvatinib, Tislelizumab Combined with Gemcitabine and Cisplatin (GPLET) in the Treatment of Advanced Cholangiocarcinoma

Recruiting
3
80
RoW
Lenvatinib, tislelizumab, gemcitabine and cisplatin, Gemcitabine and cisplatin
Second Affiliated Hospital, School of Medicine, Zhejiang University, The First Affiliated Hospital of Zhengzhou University, The Affiliated Tumor Hospital of Xinjiang Medical University
Advanced Cholangiocarcinoma
12/26
12/27
SEARCH, NCT05718232: SBRT Plus Lenvatinib and TACE for Advanced Primary HCC: A Phase 3 Trial

Not yet recruiting
3
136
RoW
Lenvatinib, TACE, SBRT
Sun Yat-sen University
Advanced Hepatocellular Carcinoma
02/27
02/27
NCT05342194: Toripalimab Plus Lenvatinib and Gemcitabine-based Chemotherapy in 1L Treatment of Advanced ICC: a Phase III Study

Not yet recruiting
3
480
RoW
Toripalimab, Tuoyi, Lenvatinib mesylate capsules, LENVIMA, Placebo IV, Toripalimab placebo, Oral placebo, Lenvatinib mesylate capsules placebo, Oxaliplatin for injection, Gemcitabine hydrochloride, Cisplatin
Shanghai Junshi Bioscience Co., Ltd.
Intrahepatic Cholangiocarcinoma
05/27
05/27
MK-6482-012 China Extension, NCT05899049: A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, vs Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)-China Extension Study

Active, not recruiting
3
249
RoW
Pembrolizumab, MK-3475, KEYTRUDA®, Belzutifan, MK-6482, PT2977, WELIREG™, Pembrolizumab/Quavonlimab, MK-1308A, Lenvatinib, MK-7902, E7080, LENVIMA®
Merck Sharp & Dohme LLC, Eisai Inc.
Carcinoma, Renal Cell
12/26
12/26
HAIC, NCT06041477: Concurrently vs Sequentially Combined With Targeted and Immunotherapy in Potentially Resectable HCC

Recruiting
3
540
RoW
Oxaliplatin,calcium folinic acid, levofolinic acid, 5-FU, Hepatic arterial infusion chemotherapy (HAIC), Concurrent Lenvatinib, Concurrent targeted therapy, Concurrent PD-1 antibody, Concurrent immunotherapy, Sequential Lenvatinib, Sequential targeted therapy, Sequential PD-1 antibody, Sequential immunotherapy
Sun Yat-sen University, The First Affiliated Hospital, Guangzhou University of Traditional Chinese Medicine, Affiliated Hospital of Guangdong Medical University, First People's Hospital of Foshan
Hepatocellular Carcinoma, Chemotherapy Effect, Chemotherapeutic Toxicity
07/27
07/30
NCT05985798: Sintilimab+Bevacizumab+TACE vs. Lenvatinib+TACE for Advanced HCC

Recruiting
3
258
RoW
Sin-Bev-TACE, Len-TACE
Second Affiliated Hospital of Guangzhou Medical University, Affiliated Hospital of Guangdong Medical University, Zhongshan People's Hospital, Guangdong, China, Lecong Hospital, Shunde District, Foshan, First People's Hospital of Foshan, Affiliated Cancer Hospital & Institute of Guangzhou Medical University
Hepatocellular Carcinoma Non-resectable
07/27
07/27
LEAP-012, NCT04246177 / 2019-002345-37: Safety and Efficacy of Lenvatinib (E7080/MK-7902) With Pembrolizumab (MK-3475) in Combination With Transarterial Chemoembolization (TACE) in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma (MK-7902-012/E7080-G000-318/)

Calendar Jan 2025 - Dec 2025: Data from LEAP-012 trial for incurable/non-metastatic HCC
Active, not recruiting
3
450
Europe, Japan, US, RoW
Lenvatinib, MK-7902, E7080, LENVIMA®, Pembrolizumab, MK-3475, KEYTRUDA®, Oral Placebo, IV Placebo, TACE
Merck Sharp & Dohme LLC, Eisai Inc.
Carcinoma, Hepatocellular
06/28
12/29
ChiCTR2400090517: An open, multicenter, randomized controlled study of the efficacy and safety of lenvatinib and tirellizumab adjuvant therapy in patients with high-risk relapsing factors for hepatocellular carcinoma

Not yet recruiting
3
328
 
Lenvatinib in combination with tirellizumab; Active monitoring
Affiliated Hospital of Guangdong Medical University; Affiliated Hospital of Guangdong Medical University, Affiliated Hospital of Guangdong Medical University
hepatocellular carcinoma
 
 
KEYNOTE-587, NCT03486873 / 2017-004417-42: Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/)

Recruiting
3
3500
Europe, Canada, Japan, US, RoW
Pembrolizumab, MK-3475, KEYTRUDA®, Standard of Care (SOC), Lenvatinib, Olaparib, Lynparza, MK-4280, Favezelimab, MK-4280A
Merck Sharp & Dohme LLC, Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Merck Sharp & Dohme LLC, Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., MerckSharp&DohmeCorp, a subsidiary of Merck&Co,Inc
Solid Tumors, Hematologic Malignancies
08/43
08/43
NCT04909866: The Efficacy and Safety of TACE, Lenvatinib and Camrelizumab in the Treatment of BCLC Stage B/C Hepatocellular Carcinoma: a Single-arm, Single-center, Open-label Study

Recruiting
2/3
40
RoW
TACE+Lenvatininb+Camrelizumab
Wuhan Union Hospital, China
Hepatocellular Carcinoma
09/22
12/22
NCT04669496: Phase II-III Clinical Trial of PD1 Antibody (Toripalimab), Lenvatinib and GEMOX Neoadjuvant Treatment for Resectable Intrahepatic Cholangiocarcinoma with High-risk Recurrence Factors

Recruiting
2/3
178
RoW
Neoadjuvant treatment
Shanghai Zhongshan Hospital, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 6th People's Hospital, Shanghai Public Health Clinical Center, RenJi Hospital, Shenzhen University General Hospital
Intrahepatic Cholangiocarcinoma, PD1 Antibody, Lenvatinib, Gemox Chemotherapy
12/25
12/26
NCT05001724: KN046 Plus Lenvatinib in Subject With Advanced Non-Small Cell Lung Cancer in the Failure of Anti-PD-(L)1 Agent

Terminated
2/3
16
RoW
KN046, Lenvatinib, Docetaxel
Jiangsu Alphamab Biopharmaceuticals Co., Ltd
Advanced Non-small Cell Lung Cancer
02/23
04/23
 

Download Options